

# Wayne Tam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9232125/publications.pdf>

Version: 2024-02-01

103  
papers

9,392  
citations

117619

34  
h-index

56717

83  
g-index

107  
all docs

107  
docs citations

107  
times ranked

15015  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in <i>IGH-BCL2</i> + diffuse large B-cell lymphomas. <i>Blood</i> , 2022, 139, 73-86.	1.4	13
2	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	7.0	22
3	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
4	Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma. <i>Leukemia</i> , 2021, 35, 1203-1208.	7.2	8
5	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes ( <i>JAK2/MPL/CALR</i> ) and <i>SF3B1</i> . <i>Modern Pathology</i> , 2021, 34, 20-31.	5.5	9
6	T-cell neoplasms in the spleen. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 135-143.	1.5	0
7	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	3.4	20
8	GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. <i>Leukemia Research</i> , 2021, 100, 106495.	0.8	2
9	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.	5.5	8
10	Myeloid, mast cell, histiocytic and dendritic cell neoplasms and proliferations involving the spleen. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 144-153.	1.5	0
11	In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. <i>Current Protocols</i> , 2021, 1, e96.	2.9	1
12	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44.	5.4	20
13	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.5	21
14	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. <i>Frontiers in Oncology</i> , 2021, 11, 701318.	2.8	10
15	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. <i>ELife</i> , 2021, 10, .	6.0	19
16	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. <i>Life Science Alliance</i> , 2021, 4, e202000955.	2.8	56
17	Meet the Associate Editor. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2021, 10, 2-2.	1.2	0
18	Diffuse Large B Cell Pdx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. <i>Blood</i> , 2021, 138, 2406-2406.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. <i>Blood</i> , 2021, 138, 2395-2395.	1.4	1
20	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021, 138, 704-704.	1.4	0
21	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 13094.	3.3	8
22	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	5.2	22
23	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
24	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020, 105, 2432-2439.	3.5	16
25	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
26	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	13.2	35
27	Myeloid neoplasms with isolated del(5q) and <i>JAK2</i> V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features?. <i>Haematologica</i> , 2020, 105, e276-e279.	3.5	14
28	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	27.8	206
29	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. <i>Nature</i> , 2019, 7, 272.		22
30	Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse. <i>Blood Cancer Journal</i> , 2019, 9, 69.	6.2	4
31	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
32	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2838-2840.	1.3	24
33	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.4	106
34	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.	5.5	50
35	Assessment of the Utility of Cytology and Flow Cytometry of Cerebrospinal Fluid Samples in Clinical Practice. <i>Acta Cytologica</i> , 2018, 62, 130-136.	1.3	5
36	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. <i>Blood</i> , 2018, 131, 1415-1424.	1.4	160

#	ARTICLE	IF	CITATIONS
37	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018, 8, 1632-1653.	9.4	120
38	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. <i>Cancer Research</i> , 2018, 78, 3413-3420.	0.9	31
39	Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. <i>Journal of Hematology and Oncology</i> , 2018, 11, 105.	17.0	26
40	A multimodality workup of patients with Hypereosinophilia. <i>American Journal of Hematology</i> , 2018, 93, 1337-1346.	4.1	14
41	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , 2017, 7, 506-521.	9.4	43
42	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2017, 102, 1352-1360.	3.5	62
43	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	3.8	39
44	The effect of initial molecular profile on response to recombinant interferon- $\alpha$ (rIFN $\alpha$ ) treatment in early myelofibrosis. <i>Cancer</i> , 2017, 123, 2680-2687.	4.1	48
45	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq1 1 0.784314 rgBT /Overlock 10 chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017, 30, 1213-1222.	5.5	52
46	Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion. <i>Scientific Reports</i> , 2017, 7, 1145.	3.3	17
47	An intrasinusoidal extracavitary variant of primary effusion lymphoma. <i>Blood</i> , 2017, 130, 836-836.	1.4	4
48	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	9.4	218
49	Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant. <i>Pediatric Blood and Cancer</i> , 2016, 63, 935-937.	1.5	7
50	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016, 29, 854-864.	5.5	104
51	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	28.9	204
52	Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis. <i>Annals of Diagnostic Pathology</i> , 2016, 25, 85-91.	1.3	6
53	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. <i>Npj Genomic Medicine</i> , 2016, 1, .	3.8	68
54	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFN $\alpha$ ) Treatment in Early Myelofibrosis. <i>Blood</i> , 2016, 128, 944-944.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 3520-3532.	1.8	26
56	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. <i>Blood</i> , 2016, 128, 735-735.	1.4	0
57	The tumor virus landscape of AIDS-related lymphomas. <i>Blood</i> , 2015, 125, e14-e22.	1.4	67
58	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015, 125, 1061-1072.	1.4	281
59	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. <i>Journal of Visualized Experiments</i> , 2015, , e53215.	0.3	7
60	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. <i>Human Pathology</i> , 2015, 46, 260-271.	2.0	63
61	Cyclin D1-Positive Diffuse Large B-Cell Lymphoma With IGH-CCND1 Translocation and BCL6 Rearrangement. <i>American Journal of Clinical Pathology</i> , 2015, 143, 288-299.	0.7	21
62	Massive splenic hamartoma with bizarre stromal cells. <i>International Journal of Hematology</i> , 2015, 101, 315-316.	1.6	4
63	Cryptococcosis in bone marrow following treatment for Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 211-212.	1.6	1
64	Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination: A Cytogenetic Finding of Potential Prognostic Value. <i>American Journal of Clinical Pathology</i> , 2015, 144, 805-810.	0.7	9
65	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	12.8	111
66	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	30.7	359
67	Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance. <i>Cancer Cell</i> , 2014, 25, 350-365.	16.8	203
68	Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. <i>Genome Biology</i> , 2014, 15, 432.	8.8	71
69	EBV Microrna Mir-BHRF1-2 Targets PRDM1/Blimp1: Potential Role in EBV Lymphomagenesis. <i>Blood</i> , 2014, 124, 3547-3547.	1.4	0
70	Aberrantly sustained PAX5 expression in plasma cell differentiation is a frequent feature in lymphoplasmacytic lymphoma but not marginal zone lymphoma in bone marrow. <i>Journal of Hematopathology</i> , 2013, 6, 169-177.	0.4	0
71	Diffuse variant of lymphocyte-predominant Hodgkin lymphoma: a diagnostic challenge. <i>Journal of Hematopathology</i> , 2013, 6, 145-150.	0.4	0
72	Inactivation Of BANK1 By a Novel IGH-Associated Translocation and 5mC <sup>TM</sup> Hypermethylation In B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 2497-2497.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 634-634.	1.4	2
74	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. <i>Blood</i> , 2013, 122, 79-79.	1.4	1
75	IL10 Receptor $\alpha$ Is a Novel Therapeutic Target That Is Epigenetically Disregulated in Low Grade Lymphomas with Plasmacytic Differentiation.. <i>Blood</i> , 2012, 120, 2383-2383.	1.4	0
76	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. <i>Blood</i> , 2012, 120, 899-899.	1.4	0
77	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	1.4	3
78	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , 2011, 118, 1617-1617.	1.4	0
79	Promoter and Exon 1 Hypermethylation of the Tumor Suppressor Gene PRDM1/Blimp-1 indicates Its Pathogenetic Role in EBV-Positive Burkitt Lymphoma,. <i>Blood</i> , 2011, 118, 3471-3471.	1.4	0
80	Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation. <i>Blood</i> , 2011, 118, 1579-1579.	1.4	7
81	MicroRNAs of the immune system. <i>Annals of the New York Academy of Sciences</i> , 2010, 1183, 183-194.	3.8	149
82	Epigenetic Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B Cell Lymphomas. <i>American Journal of Pathology</i> , 2010, 177, 1470-1479.	3.8	56
83	TNFAIP3 (A20) Genetic Alterations In EBV Associated AIDS Related Lymphomas. <i>Blood</i> , 2010, 116, 802-802.	1.4	0
84	MicroRNA-155 Modulates Transforming Growth Factor- $\beta$ Signaling In Chronic Lymphocytic Leukemia through Targeting of Casein Kinase $\beta$ Isoform 2. <i>Blood</i> , 2010, 116, 3584-3584.	1.4	0
85	Microenvironment-Mediated Regulation of Micrnas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.. <i>Blood</i> , 2010, 116, 3853-3853.	1.4	53
86	Reticuloendotheliosis Virus Strain T Induces miR-155, Which Targets JARID2 and Promotes Cell Survival. <i>Journal of Virology</i> , 2009, 83, 12009-12017.	3.4	95
87	Micro-classifying diffuse large B-cell lymphomas. <i>Blood</i> , 2009, 113, 6506-6507.	1.4	1
88	ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 4686-4686.	1.4	0
89	MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas. <i>American Journal of Pathology</i> , 2008, 173, 242-252.	3.8	154
90	The Emergent Role of MicroRNAs in Molecular Diagnostics of Cancer. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 411-414.	2.8	22

#	ARTICLE	IF	CITATIONS
91	Significance of PRDM1 <sup>2</sup> expression as a prognostic marker in diffuse large B-cell lymphomas. <i>Blood</i> , 2008, 111, 2488-2489.	1.4	6
92	Genomic Analyses Reveal Global Functional Alterations That Promote Tumor Growth and Novel Tumor Suppressor Genes in Natural Killer-Cell Malignancies. <i>Blood</i> , 2008, 112, 3792-3792.	1.4	0
93	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. <i>Cell</i> , 2007, 129, 1401-1414.	28.9	3,390
94	MicroRNAs in Tumorigenesis. <i>American Journal of Pathology</i> , 2007, 171, 728-738.	3.8	200
95	Lack of A563G (I188V) missense mutation in RIZ1/PRDM2 in human diffuse large B-cell lymphomas. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 416-418.	2.8	7
96	Quantitative Assessment of DNA Editing Enzymes in B-Cell Lymphomas. <i>Blood</i> , 2007, 110, 4687-4687.	1.4	0
97	MicroRNA-Mediated Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2007, 110, 3187-3187.	1.4	0
98	Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. <i>Blood</i> , 2006, 107, 4090-4100.	1.4	203
99	miR-155/BIC as an oncogenic microRNA. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 211-212.	2.8	110
100	Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034. <i>Blood</i> , 2006, 108, 2023-2023.	1.4	0
101	Accumulation of miR-155 and BIC RNA in human B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3627-3632.	7.1	1,295
102	Avian bic, a Gene Isolated from a Common Retroviral Site in Avian Leukosis Virus-Induced Lymphomas That Encodes a Noncoding RNA, Cooperates with c-myc in Lymphomagenesis and Erythroleukemogenesis. <i>Journal of Virology</i> , 2002, 76, 4275-4286.	3.4	152
103	Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. <i>Gene</i> , 2001, 274, 157-167.	2.2	229